Today: 7 June 2026
Portnoy’s Bitcoin, XRP Losses Mount In $390B Crypto Drop
7 June 2026
2 mins read

Portnoy’s Bitcoin, XRP Losses Mount In $390B Crypto Drop

NEW YORK, June 6, 2026, 18:03 (EDT)

Dave Portnoy says he’s not selling his Bitcoin or XRP, even as his crypto portfolio is down millions. The Barstool Sports founder has become a high-profile retail holder hit hard by the sharp crypto drop. In a video posted June 4 on X, Portnoy said he still owns Bitcoin, XRP and Strategy stock. “I have not made a cent in crypto, I have gotten whacked in crypto,” he said. TheStreet

Timing is important here. Bitcoin and Ether were heading for their steepest weekly drop since the FTX collapse in 2022. The digital-asset market shed about $390 billion. Exchanges liquidated nearly $7 billion in leveraged trades as margin slipped. Liquidation means exchanges shut down borrowed positions after traders can’t cover the margin.

Bitcoin hovered near $60,719 late Saturday in New York. XRP was sitting at $1.088. Shares in Strategy, the Bitcoin-heavy firm that used to be called MicroStrategy, changed hands last at $120.44.

Portnoy is hurting on his XRP position. CryptoNews.net, citing his posts, reported he bought in near $1.70 and burned through most of his spare cash as he tried to buy the dip.

Strategy surprised the market. A filing out June 1 showed it sold 32 Bitcoin from May 26 to May 31, bringing in $2.5 million at an average price of $77,135. The company said the move was to pay out distributions on preferred stock. Preferred stock pays dividends before common shares. Even after the sale, Strategy still had 843,706 Bitcoin, with an average cost of $75,699, according to the same filing.

Strategy sold a small amount of Bitcoin, but the market noticed. Investors have seen the firm as a regular Bitcoin buyer, so news of the sale got some wondering if Strategy could unload more to cover its preferred share obligations.

Bitcoin could see gains long-term if leveraged companies hold fewer coins, Zach Pandl, Grayscale’s head of research, said. But right now, “Other buyers will need to step in for bitcoin’s price to find a sustainable bottom,” Pandl said. CoinDesk

Money chasing artificial intelligence stocks and big IPOs is another source of pressure, K33 Research head Vetle Lunde said. That makes it tougher for some investors to overlook the “opportunity cost of holding BTC,” according to Lunde. CoinDesk

Michael Saylor, executive chairman at Strategy, argued Bitcoin hadn’t been weakened. “This is a capital rotation, not a Bitcoin impairment. Volatility creates opportunity,” Saylor wrote on X, CoinDesk reported. CoinDesk

Bullish CEO Tom Farley said “money and attention” are moving to things like AI and IPOs. Farley pushed for U.S. lawmakers to act on the CLARITY Act, a law to create digital asset rules. “We absolutely need the Clarity Act,” he said. CoinDesk

The drop has spilled over from tokens to stocks. Shares of Coinbase, Robinhood, and Circle—public companies with links to crypto trading or stablecoins—each lost ground in their latest sessions. Coinbase and Robinhood dropped around 7%. Circle fell about 11%.

Portnoy says he won’t sell, pointing partly to a Bitcoin bull thesis he’s repeated for a while. He’s mentioned Jack Dorsey, the former Twitter CEO, who said to Pirate Wires in 2024 that Bitcoin could hit “at least a million” dollars by 2030, TheStreet reported. TheStreet

Portnoy’s trade is under stress. ETF outflows aren’t stopping, bond yields are still up, and Strategy might dump more Bitcoin. Portnoy said he’s almost out of cash to buy any dip. If fresh buyers show up, holding could pay off, but right now the market’s still sizing up whether this “blood on the streets” is a buy signal or just more pain. CoinDesk

Stock Market Today

  • Why Americas Gold and Silver Shares Drop 19.7% Despite High-Grade Cosalá Drill Results
    June 6, 2026, 6:16 PM EDT. Americas Gold and Silver (TSX:USA) shares fell 19.7% following the announcement of infill drill results at its Cosalá Complex, which revealed silver grades up to five times higher than the current resource model. The company is conducting its largest drilling program through 2026, aiming to revise its mine plan and reserves to reflect these findings. Despite the promising grades, the stock decline reflects investor concerns over recent dilution, insider selling, a new management team, and execution risks across its Cosalá, Galena, and Crescent projects. The shares currently trade below some fair value estimates ranging from US$12.29 to US$33.60, highlighting divergent views on the company's prospects. Key near-term catalysts include reserve updates, 2026 production guidance, and Crescent's timely restart without additional financial strain.

Latest articles

Portnoy’s Bitcoin, XRP Losses Mount In $390B Crypto Drop

Portnoy’s Bitcoin, XRP Losses Mount In $390B Crypto Drop

7 June 2026
Strategy’s surprise sale of 32 Bitcoin for $2.5 million to fund preferred stock distributions rattled investors, raising fears it may sell more to meet obligations, as Bitcoin and Ether posted their worst weekly losses since 2022 and crypto-linked stocks like Coinbase and Robinhood plunged up to 11% amid a $390 billion market wipeout.
Bitcoin Hits $60,000 As Crypto Selloff Deepens

Bitcoin Drops as ETF Outflows Mount, $60,000 Support Weakens

7 June 2026
Bitcoin plunged below $60,000 for the first time since October 2024, triggering $4.4 billion in spot ETF outflows and a rare bitcoin sale by Strategy, while crypto-linked stocks tumbled and analysts warned that further drops below $59,750 could spark more selling pressure or a deeper slide.
Johnson & Johnson Shares Hold Up in Market Selloff — Looking at What May Shift JNJ Next Week

Johnson & Johnson Shares Hold Up in Market Selloff — Looking at What May Shift JNJ Next Week

6 June 2026
Johnson & Johnson jumped 2.02% to $232.77 Friday—outperforming a plunging S&P 500—after a Los Angeles jury found the company not negligent in a talc cancer lawsuit; investors now eye next week’s Goldman Sachs healthcare conference and a fresh $1.34 dividend, as J&J touts new drug launches and raised its 2026 outlook despite ongoing litigation and Stelara sales declines.
Eli Lilly Stock Sets High Ahead of Monday Data

Eli Lilly Stock Sets High Ahead of Monday Data

6 June 2026
Eli Lilly shares hit a record $1,131.42 close Friday, up 0.6%, after late-stage data showed its experimental retatrutide cut sleep apnea severity by 60.6% and knee osteoarthritis pain by up to 73.1% in obese adults; investors will watch Monday’s trade to see if the new results justify Lilly’s premium as the S&P 500 tumbled 2.64% Friday and rivals like Roche posted strong obesity-drug data.
Bitcoin Hits $60,000 As Crypto Selloff Deepens
Previous Story

Bitcoin Drops as ETF Outflows Mount, $60,000 Support Weakens

Go toTop